All posts by: Michael Zand

About Michael Zand

Parkinson’s startup Prevail raises $75M for gene therapy programs – FierceBiotech

Continue reading

2018-03-08 NEWS

FierceBiotech

Parkinson’s startup Prevail raises $75M for gene therapy programs
FierceBiotech
OrbiMed-backed Prevail Therapeutics has launched a $75 million first-round financing that will help fund development of its gene therapy for Parkinson’s disease (PD) and other programs. Prevail was set up last year by OrbiMed’s co-head of private
Prevail Gets $75M For Parkinson’s Gene Therapy, Bolstering NY BiotechXconomy
Prevail grabs $75MA round in the hunt for new gene therapies to stop the destruction caused by Parkinson’sEndpoints News
Prevail Therapeutics Announces $75 Million Series A Financing to Advance Gene Therapies for Patients with …Business Wire (press release)

all 4 news articles »

Continue reading

2018-03-08 NEWS

Bavarian Nordic Announces Phase 2 Trial Investigating …
GlobeNewswire (press release)
COPENHAGEN, Denmark, March 8, 2018 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced a new Phase 2 study, exploring the combination of its cancer vaccine, CV301 and Bristol-Myers Squibb’s nivolumab (OPDIVO®) in patients with metastatic

and more »

Continue reading

2018-03-08 NEWS

Genetic Literacy Project

Digitizing DNA: Real reasons to worry about cyberbiosecurity
Genetic Literacy Project
We’ve even hosted FBI agents from the Weapons of Mass Destruction Directorate here at Colorado State University and previously at Virginia Tech for crash courses on synthetic biology and the associated cyberbiosecurity risks. A year ago, we

Continue reading

2018-03-08 NEWS

Endpoints News

Prevail Gets $75M For Parkinson’s Gene Therapy, Bolstering NY Biotech
Xconomy
A potential gene therapy for Parkinson’s disease has just gotten a big boost thanks to one of the larger Series A investment rounds in years for a New York biotech. The funding, for Prevail Therapeutics, provides another jolt for the city’s life
Prevail grabs $75MA round in the hunt for new gene therapies to stop the destruction caused by Parkinson’sEndpoints News
Prevail Therapeutics Announces $75 Million Series A Financing to Advance Gene Therapies for Patients with …Business Wire (press release)

all 3 news articles »